Whereas the single use of anti-PD-1 antibody failed to induce significant antitumor effect in this study, JMJD6 knockdown overcame the resistance of metastatic melanoma cells to anti-PD-1 treatment, suggesting the combination potential of JMJD6 inhibition with ICB therapies. The gene discussed is JMJD6; the disease is metastatic melanoma.